Genetically modified 'serial killer' T cells obliterate tumors in leukemia patients
- Details
- Category: Research
In a cancer treatment breakthrough 20 years in the making, researchers from the University of Pennsylvania's Abramson Cancer Center and Perelman School of Medicine have shown sustained remissions of up to a year among a small group of advanced chronic lymphocytic leukemia (CLL) patients treated with genetically engineered versions of their own T cells.
Innovative Medicines Initiative (IMI) 4th Call 2011
- Details
- Category: Development
Based on the recommendations of the IMI Research Agenda, the IMI Governing Board has approved the IMI Annual Implementation Plan 2011, including the Scientific Priorities 2011. These priorities have been incorporated into the IMI 4th Call Topics.
CONTRACT's Questionnaire to Analyse and Improve Informed Consent in Clinical Trials
- Details
- Category: Research
In the frame of the European Project CONTRACT, which aims at analysing, improving and harmonising "informed consent" across Europe a questionnaire has been set up which will analyse the current situation concerning the legal, ethical, technical and clinical handling of consent, mainly in European projects dealing with vulnerable patient groups.
ASCO Launches Cancer.Net Mobile, a New App for iPhone, iPad, and iPod Touch
- Details
- Category: Development
The American Society of Clinical Oncology (ASCO), the world's leading professional organization representing cancer physicians, released Cancer.Net Mobile for the iPhone, iPad, and iPod Touch - a free app designed by oncologists to help people with cancer and their caregivers plan and manage cancer treatment and care.
IMI announces a new total of 23 unique projects to boost drug innovation
- Details
- Category: Research
The Innovative Medicines Initiative (IMI), currently the largest public-private partnership in the biopharmaceutical sector, launches its second wave of research projects which address key areas including cancer, immune-mediated diseases, infectious disorders and electronic health.
Harvard Medical School Faculty Advances Drug Safety Research with IBM Business Analytics
- Details
- Category: Development
IBM (NYSE: IBM) announced that faculty from Harvard Medical School and Brigham & Women's Hospital will use IBM business analytics technology at the core of new research that examines the effectiveness of prescription drugs and spots potential safety issues.
New potential drug targets discovered for preventing prostate cancer cell growth
- Details
- Category: Development
Researchers from VTT Technical Research Centre of Finland and the University of Turku have discovered four metabolic enzymes regulating prostate cancer cell growth. Inhibition of these enzymes prevents prostate cancer cell growth in cultured cells.
More Pharma News ...
- Which Pharma Product Websites are Driving Consumers to the Doctor to Request Prescriptions?
- IMS Health Forecasts Global Pharmaceutical Market Growth of 5-7 Percent in 2011, Reaching $880 Billion
- First DataBank's FIRSTLight Goes Live
- New technique to speed up drug development
- Reasons Why mHealth Apps Matters for Pharma
- Europeans are Interested in Online Patient Education Programs
- Millions unite for diabetes awareness on World Diabetes Day 2010